Pancreatic cancer — frontier options in New Jersey

8 open options

TRIALNARECRUITING
Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
Biopsy · Therapeutic Conventional Surgery · Uniformly-labeled [13C]glucose — 2 sites
TRIALPHASE2RECRUITING
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
VS-7375 · cetuximab — 28 sites
TRIALPHASE1RECRUITING
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
TJ033721 (givastomig) · TJ033721 (givastomig) , nivolumab, chemotherapy · TJ033721 (givastomig), chemotherapy — 21 sites
TRIALPHASE3RECRUITING
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Biospecimen Collection · Distal Pancreatectomy · Lanreotide — 118 sites
TRIALPHASE1RECRUITING
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
ASP2138 · Pembrolizumab · Oxaliplatin — 46 sites
TRIALPHASE1RECRUITING
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
MRTX1719 — 25 sites
TRIALPHASE1RECRUITING
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Darlifarnib · Cabozantinib · Adagrasib — 38 sites
TRIALPHASE1 / PHASE2RECRUITING
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Biopsy Procedure · Biospecimen Collection · Computed Tomography — 44 sites

Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.